Signature Authentication Can Restore Confidence - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Signature Authentication Can Restore Confidence
Signature authentication technology has evolved to become a stong tool for improving confidence in verification.


Pharmaceutical Technology



Whether to thwart illicit activities or improve compliance reporting, pharmaceutical sales operations must have confidence in the paper-based and electronic signatures they gather from physicians while in the field. The need to manage signature capture, especially in the pharmaceutical industry, is not a new challenge. FDA 21 CFR Part 11 guides the industry on this topic, as it relates to electronic signature capture. Since confirming orders or authorizing receipt of drug samples necessitates a physician's signature, the ability to authenticate a signature is the key variable in these compliance-centric processes.

Some organizations rely on paper-based signatures instead of e-signatures. In both cases, pharmaceutical companies must have the processes in place that confidently ensure that the captured signatures are genuine, are being obtained in the correct manner, and for the correct purpose. Previously, this "confidence" was based on a small random sampling of signatures that were printed and mailed to the signatories with a request that they confirm the printed signature as their own.

The primary flaw in this process is that it is based on a small sampling of the signature database, and that it relies strongly on the signatories' willingness to respond accurately to the confirmation letter. Unfortunately, because physicians now receive a barrage of these confirmation letters from pharmaceutical vendors, the quality of the response rates and resulting accuracy have diminished.


Sam Barclay
Technology has evolved to enable signatures, both electronic and on paper, to be digitally compared against previous signatures from the same author, and then rated on a scale of confidence for authenticity.

For authentication, a signature is an image. With sophisticated pattern recognition technology, the signature image is converted into digital code. The images are then compared mathematically in hundreds of ways, and the outcome is a confidence score. Equally effective in paper and electronic signatures, the confidence score indicates the likelihood that a given signature instance is a forgery or an authentic. To improve the accuracy of the process, several previously captured signatures can be used to create a reference signature, which is in effect an average of a group of signatures.

Any signatures highlighted as suspicious can then be sent for personal review or can be used to create confirmation letters to physicians. Because only suspicious signatures are sent to doctors, fewer letters are generated, and they will be targeted to only those doctors who must respond.

The benefits of electronic signature capture, as well as the ability to store and report on electronic records, are enormous. Some organizations have been reluctant to move off paper-based signatures until the risk of signature fraud can be properly mitigated through technology. Today, advances in e-signature authentication feature accurate character recognition, noise-filtering algorithms, and extraction of key data with extreme accuracy. New technology can also recognize all types of characters, such as machine print, handprint, alphanumeric sequences, international characters, and gray-scale images.

Signature authentication technology improves the complexities of the signature authentication process, increases the confidence in the outcomes and related business and compliance decisions, while enhancing customer experience.

Sam Barclay is vice-president of business development at StayinFront (Fairfield, NJ), tel. 973.461.4800,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here